Emerging Use of Immunotherapies for Resectable Melanoma
102701027010270
Melanoma remains the most common cause of death among skin cancers. Over the past decade, major leaps have been made in treating advanced melanoma, resulting in unprecedented improvement in survival. Nevertheless, a large room for improvement is still ahead. In his presentation Therapeutic Updates in Melanoma: IO for Earlier Stage Disease presented at the 2020 ODAC Dermatology, Aesthetic and Sur …
Melanoma remains the most common cause of death among skin cancers. Over the past decade, major leaps have been made in treating advanced melanoma, resulting in unprecedented improvement in survival. Nevertheless, a large room for improvement is still ahead. In his presentation Therapeutic Updates in Melanoma: IO for Earlier Stage Disease presented at the 2020 ODAC Dermatology, Aesthetic and Sur … Continue reading "Emerging Use of Immunotherapies for Resectable Melanoma"
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. David Miller, Instructor in Dermatology and Medicine at Harvard Medical School and member of the Department of Dermatology and the Department of Medicine at Massachusetts General Hospital, where he is co-director of the Merkel cell carcinoma treatment program. Watch as he shares important … 